Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
|Articles|June 3, 2011
Air Sampler
Oxoid Air Sampler is robust, flexible and easy to use. It will take any 90 or 55mm plates and is designed to monitor microbiological air quality in controlled environments. The Oxoid Air Sampler uses impaction technology that is proven to given reliable and accurate results time after time.
Advertisement
Oxoid Air Sampler is robust, flexible and easy to use. It will take any 90 or 55mm plates and is designed to monitor microbiological air quality in controlled environments. The Oxoid Air Sampler uses impaction technology that is proven to given reliable and accurate results time after time.
The Oxoid Air Sampler is a high specification air sampler designed to monitor microbiological air quality in controlled pharmaceutical, clinical and food processing environments, using proven impaction technology that has been used reliably in quality assurance and infection control applications for many years.
This compact and easily portable system, which can be modified to take 90 or 55m plates, is simple to use, with a straightforward keypad menu to lead the user through a variety of preset or user-defined functions, including:
- flexible sampling volumes
- delayed start feature
- multiple run
- variable interval.
The Oxoid Air Sampler can be operated manually or using an infra-red remote control – ideal for monitoring highly sensitive, closed environments.
For added convenience, it comes with a rechargeable battery, which allows for approximately 5 to 7 hours operation. Air intake of up to 100L/min. ensures efficient sampling and a Pyramid Quality Check system is available for confirming performance on-site. Oxoid Air Samplers can be obtained with heads of aluminium, or stainless steel that can be autoclaved.
Find out more here:
Advertisement
Related to this article
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Advertisement
Advertisement